A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

  • Giuseppe Curigliano
  • , Geoffrey I. Shapiro
  • , Rebecca S. Kristeleit
  • , Albiruni R. Abdul Razak
  • , Stephen Leong
  • , Maria Alsina
  • , Antonio Giordano
  • , Karen A. Gelmon
  • , Erica Stringer-Reasor
  • , Ulka N. Vaishampayan
  • , Mark Middleton
  • , Anthony J. Olszanski
  • , Hope S. Rugo
  • , Kenneth A. Kern
  • , Nuzhat Pathan
  • , Rachelle Perea
  • , Kristen J. Pierce
  • , Sarah C. Mutka
  • , Zev A. Wainberg

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science